<p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）在周一发布的报告中被巴克莱升级为 “强烈卖出” 评级，Zacks.com 报道。</p>
<p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<ul>
<li>道琼斯表现最好的股票默克准备发布第四季度财报</li>
</ul>
<p>其他几家研究公司也最近对 OGN 进行了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Organon &amp; Co.的 “卖出（d+）” 评级。Piper Sandler 将 Organon &amp; Co.的评级从 “增持” 下调至 “减持”，并设定了 5.00 美元的股票目标价。在 10 月 27 日的研究报告中，摩根士丹利将 Organon &amp; Co.的目标价从 10.00 美元下调至 9.00 美元，并在 11 月 11 日的报告中为该公司设定了 “持平” 评级。最后，摩根大通将 Organon &amp; Co.的目标价从 14.00 美元下调至 12.00 美元，并在 11 月 11 日的报告中为该股票设定了 “减持” 评级。一位投资分析师对该股票给予了强烈买入评级，两位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，共识目标价为 8.38 美元。</p>
<p><strong>获取我们对 Organon &amp; Co.的最新分析</strong></p>
<h2>Organon &amp; Co. 股价下跌 5.0%</h2>
<ul>
<li>Lululemon Athletica 因进入标准普尔 500 指数而创下新高</li>
</ul>
<p>周一，纽约证券交易所 OGN 的开盘价为 6.93 美元。该公司的 50 日移动平均线为 8.15 美元，200 日移动平均线为 9.20 美元。该公司的债务与股本比率为 9.69，流动比率为 1.75，速动比率为 1.20。该股票的市值为 18 亿美元，市盈率为 3.61，PEG 比率为 1.56，贝塔系数为 0.57。Organon &amp; Co.的年内最低价为 6.18 美元，年内最高价为 17.23 美元。</p>
<p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）最后一次发布季度财报是在 11 月 10 日。该公司报告本季度每股收益（EPS）为 1.01 美元，超出分析师的共识预期 0.93 美元，超出 0.08 美元。该公司本季度的收入为 16 亿美元，而共识预期为 15.7 亿美元。Organon &amp; Co.的净利润率为 7.95%，股本回报率为 143.47%。去年同期，该公司每股收益为 1.38 美元。股票研究分析师预测，Organon &amp; Co.在当前年度将发布 3.68 美元的每股收益。</p>
<h2>对 Organon &amp; Co.的对冲基金看法</h2>
<p>一些机构投资者最近增加或减少了对该公司的持股。Ransom Advisory Ltd 在第一季度购买了 Organon &amp; Co.的新股份，价值约 32,000 美元。Hanson &amp; Doremus Investment Management 在第二季度购买了 Organon &amp; Co.的新头寸，价值约 26,000 美元。Hantz Financial Services Inc.在第二季度将其在 Organon &amp; Co.的持股增加了 293.8%。Hantz Financial Services Inc.现在拥有该公司 2,674 股股票，价值 26,000 美元，此前在上个季度购买了 1,995 股。Foster Dykema Cabot &amp; Partners LLC 在第三季度购买了 Organon &amp; Co.的新股份，价值约 29,000 美元。最后，Brooklyn Investment Group 在第一季度将其在 Organon &amp; Co.的持股增加了 1,012.3%。Brooklyn Investment Group 现在拥有该公司 3,070 股股票，价值 46,000 美元，此前在上个季度购买了 2,794 股。77.43% 的股票目前由机构投资者持有。</p>
<h2>Organon &amp; Co. 公司简介</h2>
<p>（获取免费报告）</p>
<p>Organon &amp; Co.是一家基于科学的全球制药公司，通过一系列处方疗法在女性健康、生物类似药和成熟品牌领域开发和提供创新健康解决方案。该公司成立于 2020 年 3 月 11 日，总部位于新泽西州泽西市。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Organon &amp; Co.更好</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>投资于 5G 技术的顶级股票</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆发</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p>
<p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Organon &amp; Co.吗？</h2>
<p>在考虑 Organon &amp; Co.之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Organon &amp; Co.并不在名单上。</p>
<p>虽然 Organon &amp; Co.目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>巴克莱将 Organon & Co.的评级上调至 “强烈卖出”，而其他公司则给出了不同的评级，包括 “卖出” 和 “低配”。该股票开盘价为 6.93 美元，市值为 18 亿美元。Organon 报告的每股收益为 1.01 美元，超出预期。机构投资者正在调整持股，拥有 77.43% 的股份。Organon 是一家专注于女性健康和生物仿制药的制药公司</p>

<p>Organon &amp; Co. (NYSE:OGN - Get Free Report) was upgraded by Barclays to a &#34;strong sell&#34; rating in a report issued on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）在周一发布的报告中被巴克莱升级为 “强烈卖出” 评级，Zacks.com 报道。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>道琼斯表现最好的股票默克准备发布第四季度财报</li>
</ul>
</div><p>Several other research firms also recently commented on OGN. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a research note on Wednesday, October 8th. Piper Sandler cut Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 price target on the stock. in a research report on Monday, October 27th. Morgan Stanley decreased their price objective on Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating for the company in a report on Tuesday, November 11th. Finally, JPMorgan Chase &amp; Co. dropped their price objective on shares of Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Reduce&#34; and a consensus price target of $8.38.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 OGN 进行了评论。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Organon &amp; Co.的 “卖出（d+）” 评级。Piper Sandler 将 Organon &amp; Co.的评级从 “增持” 下调至 “减持”，并设定了 5.00 美元的股票目标价。在 10 月 27 日的研究报告中，摩根士丹利将 Organon &amp; Co.的目标价从 10.00 美元下调至 9.00 美元，并在 11 月 11 日的报告中为该公司设定了 “持平” 评级。最后，摩根大通将 Organon &amp; Co.的目标价从 14.00 美元下调至 12.00 美元，并在 11 月 11 日的报告中为该股票设定了 “减持” 评级。一位投资分析师对该股票给予了强烈买入评级，两位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “减持”，共识目标价为 8.38 美元。</p>
</div><p><strong>Get Our Latest Analysis on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Organon &amp; Co.的最新分析</strong></p>
</div><h2>Organon &amp; Co. Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股价下跌 5.0%</h2>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 因进入标准普尔 500 指数而创下新高</li>
</ul>
</div><p>NYSE OGN opened at $6.93 on Monday. The business's fifty day moving average is $8.15 and its 200-day moving average is $9.20. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 3.61, a PEG ratio of 1.56 and a beta of 0.57. Organon &amp; Co. has a one year low of $6.18 and a one year high of $17.23.</p>
<div class="lb-trans"><p>周一，纽约证券交易所 OGN 的开盘价为 6.93 美元。该公司的 50 日移动平均线为 8.15 美元，200 日移动平均线为 9.20 美元。该公司的债务与股本比率为 9.69，流动比率为 1.75，速动比率为 1.20。该股票的市值为 18 亿美元，市盈率为 3.61，PEG 比率为 1.56，贝塔系数为 0.57。Organon &amp; Co.的年内最低价为 6.18 美元，年内最高价为 17.23 美元。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.08. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon &amp; Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same quarter last year, the company posted $1.38 earnings per share. Equities research analysts predict that Organon &amp; Co. will post 3.68 EPS for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）最后一次发布季度财报是在 11 月 10 日。该公司报告本季度每股收益（EPS）为 1.01 美元，超出分析师的共识预期 0.93 美元，超出 0.08 美元。该公司本季度的收入为 16 亿美元，而共识预期为 15.7 亿美元。Organon &amp; Co.的净利润率为 7.95%，股本回报率为 143.47%。去年同期，该公司每股收益为 1.38 美元。股票研究分析师预测，Organon &amp; Co.在当前年度将发布 3.68 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Organon &amp; Co.</h2>
<div class="lb-trans"><h2>对 Organon &amp; Co.的对冲基金看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the business. Ransom Advisory Ltd bought a new stake in shares of Organon &amp; Co. during the 1st quarter valued at about $32,000. Hanson &amp; Doremus Investment Management bought a new position in shares of Organon &amp; Co. in the second quarter worth approximately $26,000. Hantz Financial Services Inc. raised its stake in Organon &amp; Co. by 293.8% in the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company's stock valued at $26,000 after purchasing an additional 1,995 shares in the last quarter. Foster Dykema Cabot &amp; Partners LLC bought a new stake in Organon &amp; Co. during the third quarter valued at approximately $29,000. Finally, Brooklyn Investment Group grew its stake in Organon &amp; Co. by 1,012.3% in the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock worth $46,000 after buying an additional 2,794 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该公司的持股。Ransom Advisory Ltd 在第一季度购买了 Organon &amp; Co.的新股份，价值约 32,000 美元。Hanson &amp; Doremus Investment Management 在第二季度购买了 Organon &amp; Co.的新头寸，价值约 26,000 美元。Hantz Financial Services Inc.在第二季度将其在 Organon &amp; Co.的持股增加了 293.8%。Hantz Financial Services Inc.现在拥有该公司 2,674 股股票，价值 26,000 美元，此前在上个季度购买了 1,995 股。Foster Dykema Cabot &amp; Partners LLC 在第三季度购买了 Organon &amp; Co.的新股份，价值约 29,000 美元。最后，Brooklyn Investment Group 在第一季度将其在 Organon &amp; Co.的持股增加了 1,012.3%。Brooklyn Investment Group 现在拥有该公司 3,070 股股票，价值 46,000 美元，此前在上个季度购买了 2,794 股。77.43% 的股票目前由机构投资者持有。</p>
</div><h2>Organon &amp; Co. Company Profile</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p>
<div class="lb-trans"><p>Organon &amp; Co.是一家基于科学的全球制药公司，通过一系列处方疗法在女性健康、生物类似药和成熟品牌领域开发和提供创新健康解决方案。该公司成立于 2020 年 3 月 11 日，总部位于新泽西州泽西市。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Insiders Are Selling These 3 Stocks—Here’s Why</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Organon &amp; Co.更好</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>内部人士正在出售这三只股票——原因在这里</li>
<li>投资于 5G 技术的顶级股票</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年前爆发</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=OGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Organon &amp; Co.吗？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Organon &amp; Co.之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Organon &amp; Co.并不在名单上。</p>
</div><p>While Organon &amp; Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organon &amp; Co.目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Organon & Co. (NYSE:OGN) 的股票评级被巴克莱上调